Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices-Reference-Cited by-同舟云学术

Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices

Published:2020-01-28 Issue:3 Volume:13 Page:275-287
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Takyar Jitender¹,Raut Monika²,Borse Rebekah³,Balakumaran Arun⁴,Sehgal Manu¹

Affiliation:

1. Parexel International, Mohali, India

2. Merck & Co., Inc, Kenilworth, NJ, USA

3. Merck & Co., Inc, Washington, DC, USA

4. Merck & Co., Inc, South San Francisco, CA, USA

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2020.1716725

Reference53 articles.

1. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome

2. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

3. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

4. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

5. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Результаты терапии первичной медиастинальной В-крупноклеточной лимфомы. Опыт МРНЦ им. А.Ф. Цыба (Обнинск);Clinical Oncohematology;2024-07-01

2. Prognostic factors and clinical survival outcome in patients with primary mediastinal diffuse large B-cell lymphoma in rituximab era: A population-based study;Medicine;2024-02-23

3. Major impact of prognosis by age and sex in patients with primary mediastinal large B‑cell lymphoma;Oncology Letters;2023-12-13

4. Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement;Hematological Oncology;2021-01-11

Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review

;Cancer Management and Research;2020-07